Peginterferon alfa-2b Articles
Locteron shows better AE profile than PEG-Intron
24 April 2009
FDA expands indication for S-P hep C combo
30 March 2009
Schering-Plough finally back in profit after Organon buy; exceeds expectations, pleasing shareholders
9 February 2009
S-P's Pegintron/Rebetol approved in children
22 December 2008
S-P claims superior pipeline to competitors; new drugs could make $7B in next 4 years
8 December 2008
"Unprecedented" 75% SVR24 for boceprevir
1 December 2008
S-P's boceprevir doubles SVR24 in Ph II study
10 November 2008
Pegasys/Copegus effective in non-responders
10 November 2008
S-P profit falls 21%, still up on predictions
27 October 2008
China hep C market to grow to $150M in 2012
15 September 2008
China's hep B market $800M by 2012
8 September 2008
S-P's boceprevir shows 74% SVR in HCV
11 August 2008
EU's pediatric drug c'tee celebrates first birthday
28 July 2008
S-P profit down again on Organon charges
28 July 2008
S-P's boceprevir sees 57% SVR at 28 weeks
5 May 2008
Similar SVRs for S-P and Roche HCV combos
5 May 2008
OctoPlus' Locteron impresses in Ph I study
17 March 2008
S-P's 4th-qtr 2007 results hit by Organon buy
18 February 2008
OctoPlus begins dosing in US Locteron study
11 February 2008
Further EU approval for S-P's HCV drug combo
26 November 2007
Pegintron plus Rebetol achieves consistent SVR
21 November 2007
S-P's boceprevir boosts HCV clearance rates
29 October 2007
S-P's 3rd-qtr 2007 net income surges 149%
29 October 2007
CHMP recommends S-P's HCV drug regimen
1 October 2007
Drug Royalty buys 25% of Peg-Intron royalties
3 September 2007
S-P's 2nd-quarter 2007 EPS doubles to $0.34
30 July 2007
Schering-Plough 1st-qtr profits leap 55%
30 April 2007
S-P's Pegintron cleared in China for HBV
16 April 2007
S-P announces its AASLD presentation program
6 November 2006
S-P's 3rd-qtr 2006 net income improves
30 October 2006
UK OKs combination hepatitis C treatments
4 September 2006
New indications in Japan for S-P drugs
9 January 2006
NZ Pharmac gets budget boost, OKs new Rx uses
8 August 2005
Schering-Plough expands in Asia Pacific
18 July 2005
PegIntron/ribavirin 12-week therapy effective
4 July 2005
Clarification:
28 April 2005
PegIntron/Rebetol in HCV: positive data
25 April 2005
Schering-Plough back in profit for 1st-qtr
22 April 2005
Schering-Plough aims for 100B yen sales in Japan by 2010
18 April 2005
S-P's Peg-Intron launched in Japan
20 December 2004
Schering-Plough's Peg-Intron OKed in Japan
1 November 2004
Schering-Plough cutting jobs in Ireland
19 January 2004
EU changes label for S-P's PegIntron
27 October 2003
S-P to compare hep C therapies
6 October 2003
New data show PegIntron should be given twice-weekly
4 August 2003
S-P, Novartis link up on asthma product
21 April 2003
Roche undercuts rival with ribavirin brand
20 January 2003
Ribapharm sues Roche for patent infringement
12 August 2002
FDA grants Pegasys fast-track review
22 July 2002
Ribapharm confident on 2nd-qtr results
15 July 2002
Roche gets OKs for Pegasys, Copegus
1 July 2002
Roche's Pegasys: "unprecedented efficacy in hep C"
29 April 2002
ICN defending ribavirin patent
11 March 2002
Record revenues reported at ICN
4 March 2002
New NICE appraisal program goes for one-month consultation
25 February 2002
Enzon starts Phase II study in lung cancer
18 February 2002
S-P's PEG-Intron demand difficulties.
21 January 2002
ICN earnings to exceed expectations.
21 January 2002
Maxim initiates Ceplene Phase II trials
7 January 2002
Maxim initiates Ceplene Phase II trials
19 December 2001
S-P's PEG-Intron/ribavirin combo works in relapses
15 November 2001
Maxim to initiate Ph II Ceplene trials
8 November 2001
Sales flat at Schering-Plough as manufacturing problems persist
23 October 2001
Enzon goes into profit in 4th qtr
22 August 2001
Roche, S-P resolve peginterferon dispute
13 August 2001
ICN Pharma earnings take a downturn
3 August 2001
FDA approves Rebetol as separate treatment
31 July 2001
Flat 2nd-qtr sales/EPS at Schering-Plough
25 July 2001
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
